Madrigal Pharmaceuticals struck a licensing and option deal to add six preclinical siRNA programs from Ribo Life Science to its metabolic dysfunction‑associated steatohepatitis (MASH) portfolio, paying roughly $60 million upfront with potential milestones up to $4.4 billion. The company said the RNAi assets will be developed to complement Rezdiffra, Madrigal’s THR‑β agonist now marketed for MASH. Madrigal’s stated strategy is to combine mechanistically distinct agents—gene silencing via siRNA plus hormonal modulation via THR‑β agonism—to address multiple disease drivers in fatty‑liver disease. Small interfering RNA (siRNA) therapeutics reduce expression of specific genes; the deal signals continued heavy investment to broaden the post‑launch franchise for Rezdiffra.